Acrivon Therapeutics, Inc. (ACRV) stock
ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.56+0.13 (+9.09%)
Close on Nov 18, 2026Market cap $66.85MP/E –Yield –
Acrivon Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Acrivon Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$78.37M. For fiscal 2025 it was -$84.11M. The highest annual figure on record is -$16.18M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$84.11M | – |
| FY2024 | Dec 31, 2024 | -$89.20M | – |
| FY2023 | Dec 31, 2023 | -$67.10M | – |
| FY2022 | Dec 31, 2022 | -$32.66M | – |
| FY2021 | Dec 31, 2021 | -$16.18M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.67M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$20.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.69M | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.66M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.95M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.14M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.44M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.67M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.05M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.14M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.39M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.95M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.93M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.21M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.67M | – |
See a number that looks wrong?